Abstract:Drug induced liver injury (DILI) occurs in patients exposed to drugs at recommended doses that leads to idiosyncratic DILI and provides an excellent human model with well described clinical features, liver injury pattern, and diagnostic criteria, based on patients assessed for causality using RUCAM (Roussel Uclaf Causality Assessment Method) as original method of 1993 or its update of 2016. Overall, 81,856 RUCAM based DILI cases have been published until mid of 2020, allowing now for an analysis of mechanistic issues of the disease. From selected DILI cases with verified diagnosis by using RUCAM, direct evidence was provided for the involvement of the innate and adapted immune system as well as genetic HLA (Human Leucocyte Antigen) genotypes. Direct evidence for a role of hepatic immune systems was substantiated by (1) the detection of anti-CYP (Cytochrome P450) isoforms in the plasma of affected patients, in line with the observation that 65% of the drugs most implicated in DILI are metabolized by a range of CYP isoforms, (2) the DIAIH (drug induced autoimmune hepatitis), a subgroup of idiosyncratic DILI, which is characterized by high RUCAM causality gradings and the detection of plasma antibodies such as positive serum anti-nuclear antibodies (ANA) and anti-smooth muscle antibodies (ASMA), rarely also anti-mitochondrial antibodies (AMA), (3) the effective treatment with glucocorticoids in part of an unselected RUCAM based DILI group, and (4) its rare association with the immune-triggered Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) caused by a small group of drugs. Direct evidence of a genetic basis of idiosyncratic DILI was shown by the association of several HLA genotypes for DILI caused by selected drugs. Finally, animal models of idiosyncratic DILI mimicking human immune and genetic features are not available and further search likely will be unsuccessful. In essence and based on cases of DILI with verified diagnosis using RUCAM for causality evaluation, there is now substantial direct evidence that immune mechanisms and genetics can account for idiosyncratic DILI by many but not all implicated drugs, which may help understand the mechanistic background of the disease and contribute to new approaches of therapy and prevention.

S4427 Drug-Induced Autoimmune-Like Hepatitis and Stevens Johnsons Syndrome Secondary to Levetiracetam

[Drug-induced autoimmune-like liver injury]

Intrahepatic Cholestasis Induced by Leflunomide: An Unusual Presentation of DILI

S4576 Unique Case of Vanishing Bile Duct Syndrome Exacerbated by Noncompliance

S4189 ALF Secondary to DILI With Concurrent Acute HCV

S3977 A Rare Case of Drug Induced Liver Injury Secondary to Ustekinumab and Risankizumab in a Crohn's Disease Patient

Clinical and Liver Biochemistry Phenotypes, and Outcome in 133 Patients with Anti-seizure Drug-Induced Liver Injury

S4403 A Case of Ibuprofen Induced Autoimmune Hepatitis Resulting in Acute on Chronic Liver Failure

Secular Trends in Severe Idiosyncratic Drug-Induced Liver Injury in North America: An Update From the Acute Liver Failure Study Group Registry

Stevens-Johnson syndrome induced by levetiracetam.

Acute hepatitis in a paediatric patient: immune-mediated drug-induced liver injury or albendazole-induced autoimmune hepatitis?

Idiosyncratic drug-induced liver injury: an overview

S4269 A K(NAC)K for DILI

Uncommon Presentations of Idiosyncratic Drug-Induced Liver Injury

Molecular Idiosyncratic Toxicology of Drugs in the Human Liver Compared with Animals: Basic Considerations

Severe Drug-Induced Liver Injury From Over-the-Counter Medication

Advances in Idiosyncratic Drug-Induced Liver Injury Issues: New Clinical and Mechanistic Analysis Due to Roussel Uclaf Causality Assessment Method Use

Application of a Mechanistic Model to Evaluate Putative Mechanisms of Tolvaptan Drug-Induced Liver Injury and Identify Patient Susceptibility Factors

Drug-Induced Autoimmune Hepatitis following Treatment with Zoledronic Acid

S4397 Drug-Induced Liver Injury Secondary to Recent Ozempic use

Idiosyncratic drug-induced liver injury: an update on the 2007 overview